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Abstract
Introduction: Prior research on neglected disease drug development suggested inadequate funding was responsible for
relatively few new approvals. In response, significantly more resources have been allocated towards development of drugs
targeting neglected diseases. Our objective was to reassess drug development between1975 and 1999, evaluate progress in
neglected disease drug development since 2000, and explain how increased numbers of approvals are a necessary but
insufficient condition to improving access.
Methods: To assess numbers of approvals targeting neglected diseases, we employed two distinct methodologies: First, to
revisit numbers published in Trouiller et al. (2002) we used their method to count marketed new chemical entities (NCEs)
between 1975 and 1999. Second, using the G-Finder report as a benchmark, we identified which diseases are currently
considered ‘‘neglected’’ to tally approvals in the 1975–1999 and 2000–2009 periods. Searching PharmaProjects and IMS R&D
Focus databases as well as websites from numerous drug regulatory agencies, we identified new drug approvals and
indications. Also, we examined the World Health Organization’s (WHO) Essential Drug List (EDL) to see which drugs and
indications were on the list.
Findings: Upon recount, using Trouiller et al. methodology, we found that between 1975 and 1999 more NCEs (n=32)
targeting tropical diseases and tuberculosis were approved than reported in Trouiller et al. (n=16). Using the G-Finder
method of defining neglected diseases, we found 46 new drug approvals between 1975 and 1999. WHO included 85% of
these drugs on the EDL. In the period 2000 to May 2009, despite much greater funding, only 26 new drugs and vaccines for
neglected diseases were marketed. Of these, WHO placed 50% on the EDL.
Conclusions: Product approvals for neglected diseases have increased, though progress has been uneven, with malaria
appearing to benefit most in the short run from increased funding, while less success has been booked in other disease
categories. Uneven progress suggests funding could be better targeted, particularly with regard to neglected diseases that
have hitherto received scant attention. In addition, policymakers should focus on other aspects related to access. Besides
drug development, there are the issues of EDL listing, architecture, availability, affordability, and adoption.
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Introduction
Neglected diseases are infectious diseases that primarily,
though not exclusively, affect vulnerable populations in devel-
oping countries where poor sanitation and lack of access to
health care foster disease transmission and vector proliferation.
These diseases, which include malaria, tuberculosis, diarrheal
diseases, and kinetoplastids such as leishmaniasis, cause 35,000
deaths per day in the developing world along with significant
morbidity.[1]
There is great interest in the public health community in
developing new products to treat or prevent these diseases.
However, given limited health care budgets in most developing
nations, the general public’s weak purchasing power, and the
correspondingly low likelihood of a satisfactory return on
investment, there is comparatively little incentive for private
industry to dedicate research and development (R&D) resources to
developing medicines for these markets.[2]
In a widely cited 2002 study, Trouiller et al. reported that of
1393 new chemical entities (NCEs) marketed between 1975 and
1999, only 16 targeted ‘‘tropical diseases’’ and tuberculosis.[3]
Furthermore, Trouiller et al. found that in 1999 less than $70
million was invested in drug research and development for
malaria, tuberculosis, leishmaniasis, and African trypanosomias
combined.[4]Their study galvanized thought leaders to proclaim
the necessity of greater investment in neglected disease drug
development. As such it served as a clarion call to action for
governments, non-profit foundations, private-public partnerships,
and the private industry to earmark more resources to battle this
public health problem.
Since 1999, funding has greatly increased.[5] Additionally,
definitions of neglected disease have expanded beyond the tropical
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cooperative ventures have begun to take shape, including the
Global Network for Neglected Tropical Disease Control, Medi-
cines for Malaria Venture (MMV), the Drugs for Neglected
Diseases Initiative (DNDi), and numerous partnerships with
pharmaceutical companies, including Merck, GlaxoSmithKline,
Pfizer, Novartis and Sanofi-Aventis. According to the G-Finder
report, in 2007, $2.5 billion was invested in neglected disease drug
development, with $980 million targeting malaria, tuberculosis,
and the kinetoplastids combined. Nearly 80% of funds poured into
the ‘‘big three:’’ HIV/AIDS, tuberculosis, and malaria. Of this
amount, nearly 90% came from public or philanthropic donors,
with the National Institutes of Health and the Bill and Melinda
Gates Foundation leading the way.[6]
In comparison with a decade ago, more resources are being
spent to address the problem of neglected diseases. A way of
addressing the question of whether increased funding has been
effective is to mark progress in new approvals. A progress report
was published in 2006, which showed several new approvals over
the 2000–2004 period.[7] However, our study provides an
updated, in-depth examination of new approvals through May
of 2009. We also analyze whether new approvals are being
included in the WHO’s EDL. Together with WHO treatment
guidelines, the EDL forms the basis for public health policy in
many developing countries. Finally, we examine the larger
question of pharmaceutical access.
First, our paper revisits numbers of approved drugs targeting
‘‘tropical diseases’’ and tuberculosis previously published by
Trouiller et al. Second, we mark progress in neglected disease
drug approvals since 1999. Finally, we explain how increased
numbers of approvals are a necessary but insufficient condition to
improving access.
Methods
To assess new approvals targeting neglected diseases, we
employed two distinct methodologies: First, we used the method
in Trouiller et al. to count marketed new chemical entities (NCEs)
between 1975 and 1999, as well as fixed dose combination
products. Second, referencing the authoritative G-Finder report as
a benchmark, we identified currently defined neglected diseases to
tally approved products and indications in the 1975–1999 and
2000–2009 periods. The G-Finder report investigated funding
allocated to the following diseases: malaria, tuberculosis, bacterial
pneumonia and meningitis, pneumonia, rotavirus, enterotoxigenic
and enteroaggregative E. Coli, cholera, shigella, cryptosporidium,
giardia, Chagas disease, leishmaniasis, African trypanosomiasis,
roundworm (ascariasis), hookworm (ancylostomiasis & necatoria-
sis), whipworm (trichuriasis), strongyloidiasis and other intestinal
roundworms, lymphatic filariasis (elephantiasis), onchocerciasis
(river blindness), schistosomiasis (bilharziasis), tapeworm (cyster-
cercosis/taeniasis), leprosy, trachoma, Buruli ulcer, Dengue fever,
rheumatic fever, typhoid and paratyphoid fever, and HIV/AIDS
(products with applications specific to the developing world, such
as vaccines, microbicides and pediatric label extensions). This
enumeration of diseases builds upon Trouiller et al. Besides the
inclusion of Buruli ulcer, bacterial pneumonia and meningitis,
rheumatic fever, typhoid and paratyphoid fever, and the exclusion
of Japanese encephalitis, the biggest difference is that HIV/AIDS
drugs and anti-diarrhoeals are included in the G-Finder count, so
long as they are indicated for conditions pertinent to the
developing world. In the case of HIV/AIDS products this implies
pediatric use, vaccines and microbicides. Anti-diarrhoeal drugs
were only counted if indicated for cholera, shigella, or cryptospo-
ridium. Finally, anti-diarrhoeal vaccines were included if they
targeted one or more diseases across the entire diarrhoeal
spectrum.
In contrast to Trouiller et al., we categorized indications
separately in our G-Finder based count. If a drug received
approval for more than one disease, we counted each instance as a
newly approved indication though only one instance as a newly
approved drug. For example, mebendazole can be used for four
different helminths, so it was counted for four indications, but just
once as a newly approved drug. Note that new doses or
formulations of (combination) drugs did not count towards new
approvals.
We identified new product approvals and indications using the
PharmaProjects and IMS R&D Focus databases, websites from the
Food and Drug Administration, European Medicines Agency, and
drug regulatory agencies of France, Germany, the Netherlands,
the United Kingdom, China, Kenya, and India. We also
examined the most recent version of the EDL to see which drugs,
indications, and vaccines are recommended for use.[8]
Results
Using the same NCE count methodology employed in Trouiller
et al. we found that their figure of 16 appears to have
undercounted the total number of drugs approved for ‘‘tropical
diseases’’ and tuberculosis between 1975 and 1999; namely, 32.
Moreover, the Trouiller et al. list is inaccurate as five of the 16
drugs were not approved between 1975 and 1999.
According to our tally based on a G-Finder definition of
neglected diseases, 46 new products were approved between 1975
and 1999 targeting neglected diseases, with a total of 56
indications. Of these, 6 were for pediatric HIV (note, no
microbicides or vaccines were approved), 7 for malaria, 12 for
tuberculosis, three for bacterial pneumonia and meningitis, two
new drugs and four new indications for diarrheal diseases, two for
kinetoplastids, 9 new drugs and 16 new indications for helminths,
two for leprosy and one each for trachoma, rheumatic fever, and
typhoid fever. No new products were approved for Buruli ulcer
and Dengue fever. Of the 46 new drug approvals, 39 (85%) were
placed on the EDL. And, of the 56 new indications approved for
marketing, 46 (82%) were added to the EDL.
In table 1 we list the original Trouiller et al. numbers, our
recount of Trouiller et al., an analysis of numbers based on a
broader G-Finder definition of neglected diseases, and a tally of
percentages of drugs and indications on the EDL. The appendix
(Appendix S1) includes tables which provide a detailed count of all
approvals, their year of approval, and the regulatory authority that
made the initial approval.
Between 2000 and May 2009, 26 products for neglected
diseases were marketed with a total of 26 indications. Of these, the
WHO had placed 50% on the 2009 EDL. The greatest number of
approvals occurred in malaria with 11 new drugs being marketed.
An additional 10 new HIV/AIDS drugs were granted pediatric
labeling; one new drug and two vaccines for diarrheal diseases; one
vaccine was developed against bacterial meningitis, and one new
drug was approved for kinetoplastids. No other disease category
had any new drugs approved in the last 9 years. Table 2 lists all
products approved for neglected diseases between 2000 and May
2009 along with their EDL status.
For a complete listing of all products and indications approved
in the 1975–1999 and 2000–2009 periods, please see appendix
(Appendix S1).
The percentage of approved neglected disease products
sponsored by the private pharmaceutical industry dropped from
Drug Development and Access
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sponsored by public-private partnerships increased from 15% to
46% (see table 3). Here, sponsorship implies the sponsor paid for a
product’s development through the clinical phases.
It may be problematic to mark progress using numbers of
approvals. Clearly, many of the product development efforts that
began in 2000–2009 have not (yet) resulted in new product approvals,
given the(variable) lengthoftimebetweeninitialfunding of R&D and
registration. Indeed, collecting data on new products in clinical
development, we see promising signs as 97 are currently in the
pipeline despite the fact that certain therapeutic areas continue to be
neglected (see table 4). This said, we do not think it is far-fetched to
already be looking for indications of progress in terms of numbers of
newapprovals,particularlygiventhefactthattheconventional10–15
year period to register a drug may not invariably apply as numerous
products currently being developed by PPPs have been granted
accelerated approval times.[9]
Discussion
Regardless of how one does the counting, the 1975–1999 period
was not good for neglected disease product development.
However, since Trouiller’s call to action, there has been progress
in neglected disease product development, albeit in uneven strides.
For example, malaria has seen a 250% increase in numbers of new
products compared to the 1975–1999 period. Nevertheless,
malaria appears to be the exception rather than the rule. While
tuberculosis has received similar funding to malaria, not a single
new tuberculosis drug has been approved in the last nine years.
Although this may be in part due to longer development times for
tuberculosis products, we also observe fewer products in the
clinical development pipeline than with malaria. Likewise, despite
HIV/AIDS R&D towards applications specific to the developing
world totaling $1.8 billion in 2007, of which 64% went to vaccine
development and 18% to microbicides, no vaccines or microbi-
cides have been approved. Finally, not a single new product has
been approved in the last 9 years in disease categories that include
Buruli ulcer, Dengue fever, trachoma, rheumatic fever, or typhoid
and paratyphoid fevers.
Here, we do not wish to leave the impression that the now
predominant PPP model is not promising. Besides having
numerous products in the clinical development pipeline that
may prove invaluable, PPPs have demonstrated an ability to
develop drugs with high health impact. PPP-based products, such
as the arthemeter + lumefantrine combination, are making a
difference in the developing world.
Separate from R&D funding levels and new approvals is the
issue of inclusion on the EDL, which does not guarantee access but
may act as a lever to increase access. The EDL recommends what
it considers to be the most essential, yet cost-effective drugs
available. As such, it forms the basis for public health policy in
many developing nations.[10] There are clear linkages between
EDL, clinical practice guidelines, and drug procurement practices.
These relationships underscore the ‘‘operational, educational, and
symbolic functions of an essential drugs list:’’[11] Operational in
that the EDL identifies medicines for priority attention for
Table 1. Numbers of 1975-1999 Approvals for Neglected Diseases.
Disease Category
Trouiller et al. new chemical
entities (NCEs) targeting ‘‘tropical
diseases’’ and tuberculosis Our Analysis
Our recount of
Trouiller et al. NCEs








HIV/AIDS* n/a** n/a** 6*** 6
Malaria 4 7 7 7
Tuberculosis 3 12 12 12
Bacterial Pneumonia and Meningitis n/a** n/a** 3 3
Diarrheal Diseases n/a** n/a** 2 4
Kinetoplastids 5 2 2 2
Buruli Ulcer n/a** 0 0 1
Dengue Fever 0 0 0 0
Helminths 4 9 9 16
Leprosy 0 2 2 2
Trachoma n/a** n/a** 1 1
Rheumatic Fever n/a** n/a** 1 1
Typhoid and Paratyphoid Fever n/a** n/a** 1 1
Total Approvals 16 32 46 56
Percentage on Essential Drug List 94% 85% 85% 82%
*In their analysis, Trouiller et al. included 26 HIV drugs-20 anti-virals and 6 drugs for ‘‘opportunistic diseases’’-but as a separate (non-neglected) disease category.
**Disease categories Trouiller et al. did not include in their analysis.
***HIV/AIDS drugs with applications specific to the developing world, such as vaccines, microbicides and pediatric label extensions. Sources: PharmaProjects, IMS R&D
Focus, http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA, http://eudrapharm.eu/eudrapharm/searchbykeyword.do, http://www.cbg-meb.nl/CBG/en/human-
medicines/actueel, http://www.pharmacyboardkenya.org/index.php?id=13&dpgndg1=42&an=, http://www.who.int/medicines/publications/
08_ENGLISH_indexFINAL_EML15.pdf, http://www.cdsco.nic.in/, http://www.afssaps.fr/, http://www.mhra.gov.uk/index.htm, http://www.bmg.bund.de.
doi:10.1371/journal.pone.0010610.t001
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influences drug utilization patterns; and symbolic in that the
EDL confers global recognition and a preferred position in
pharmaceutical management.
Of the drugs targeting neglected diseases that were developed
between 1975 and 1999, 85% are on the EDL. By comparison, only
50% of products approved in the 2000–2009 period are on the EDL.
This could be due to lag time as the WHO deliberates following each
new approval, but may also be the result of the higher cost of certain
newer drugs.[12] In a severely budget-constrained environment the
low cost of older drugs may tip the scales in their favor. Needless to
say, non-admittance to the EDL can serve as an access barrier, with
possibly deleterious health outcomes.
It is often assumed that once a product is added to the EDL, the
access problem is resolved. However, besides EDL listing,
numerous barriers to access persist, the foremost being resource
constraints. Others include limited capacity of public health
systems, lack of political commitment in terms of distribution and
delivery of products and services, international trade and patent
disputes, and cultural attitudes towards disease and products to
remedy or prevent disease.[13]
Table 4. Neglected Disease Products in Clinical Development
as of July 2009.
Disease Category Drugs Vaccines Microbicides
HIV/AIDS 0 24 4
Malaria 9 19 —
Tuberculosis 5 7 —
Bacterial Pneumonia and Meningitis 0 4 —
Diarrheal Diseases 0 11 —
Kineptoplastids 4 2 —
Buruli Ulcer 0 0 —
Dengue Fever 0 3 —
Helminths 1 1 —
Leprosy 0 0 —
Trachoma 0 0 —
Rheumatic Fever 0 0 —
Typhoid and Paratyphoid Fever 0 3 —
Total 19 74 4
Sources: BIO Ventures for Global-R&D Landscape, ,http://www.bvgh.org/
resources/landscape/default.asp.; Cowen and Co. Pharmaceuticals Industry
Overview, May 2009; PhRMA Medicines in Development Factsheets for HIV/
AIDS, infectious disease, and biotechnology; International Federation of
Pharmaceutical Manufacturers and Associations, ‘‘Pharmaceutical Industry R&D
for Diseases of the Developing World-2009’’, ,http://www.ifpma.org/
documents/NR12400/Status_RnD_for_DDW_07Jul09.pdf.; ClinicalTrials.gov;
Moran, et al. (2007) ‘‘The Malaria Product Pipeline: Planning for the Future.’’ The
George Institute for International Health, ,http://www.thegeorgeinstitute.org/
research/health-policy/current-projects/the-malaria-product-pipeline-planning-
for-the-future.cfm.; websites, press releases, and reports from various PDPs
and NGOs including the Meningitis Vaccine Project, PATH (including Malaria
Vaccine Initative), Medicines for Malaria Venture, Alliance for Microbicide
Development, Drugs for Neglected Diseases Initiative, International AIDS
Vaccine Initiative, AIDS Vaccine Advocacy Coalition, Global Alliance for TB Drug
Development Note to table 4: Table 4 presents a snapshot of active drugs,
vaccines, and microbicides in clinical development for neglected diseases as of
July 2009. Using the inclusion criteria outlined in Moran et al., the majority of
products were located using commercial and public reports from trade
associations (PhRMA, IFPMA), commercial entities (Cowen and Co.), various
product development partnerships (PDPs) and NGOs (BioVentures for Global
Health), and government agencies such as the NIH and US Department of
Defense. Products were only included when their status could be verified
through secondary sources, which included clinical trial records from
ClinicalTrials.gov, information posted on company websites, and website
information from the sources listed in the table. The table should not be
considered an exhaustive list of every product in development. First, only new
products were listed, which excludes previously approved products that are
now being developed for wider use. For example, the dihydroartemisinin +
piperaquine combination currently in pre-registration was left out because it
was approved in Kenya in 2005 (see table 2), despite being considered by some
analysts as part of the pipeline. Second, our reliance on public and commercial
sources potentially overlooks other sources.
doi:10.1371/journal.pone.0010610.t004
Table 2. Numbers of 2000–2009 Approvals for G-Finder
Defined Neglected Diseases.








Diarrheal Diseases 3 3
Kinetoplastids 1 1
Buruli Ulcer 0 0












*HIV/AIDS drugs with applications specific to the developing world, such as
vaccines, microbicides and pediatric label extensions. Sources: PharmaProjects,








Table 3. Comparison of Approvals by Source of Sponsorship.
1975–1999 2000–2009
Number of Individual Products Approved 46 26
Number of Products Sponsored by PPP
(% of Total)
7 (15%) 12 (46%)
Number Sponsored by Private Industry (%) 38 (83%) 12 (46%)
Number Sponsored by Other/Unknown (%) 1 (2%) 2 (8%)
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architecture. Availability refers to ‘‘the logistics of making, ordering,
shipping, storing, distributing and delivering a new health technology
to ensure it reaches the hands (or mouth) of the user.’’[14] This
implies that even if a product travels the drug development route
successfully, reaches market, and is recommended by WHO for use,
there is still the question of how it is to be distributed to the people
who need it. Affordability encompasses both the individual patient’s
ability to pay and that of governments and other payers. This is less of
a concern for medications such as ivermectin, which Merck donates.
But, it may be an acute issue for drugs such as artemisisin-based
combination therapies.[15] Adoption runs the gamut from a
product’s recommendation by international agencies like WHO to
its acceptance by local policymakers in developing countries, to
patients as well as health care providers, some of whom may have
misgivings about taking certain products. Lastly, architecture refers to
the organizational dimension of access; decisions about organiza-
tional structure that are required for coordinating availability,
affordability, and adoption. In this context, consider, for example,
the anti-helminths. Given that there are already 9 drugs that are
effective at treating helminths, it appears that the need for
development of new anti-helminths is less critical than the need for
improved access. Hence, the helminths appear to be neglected
diseases not because of a drug deficit but due to limited effective
means of getting these drugs to the people who need them.
In sum, funding of neglected disease R&D is highly concen-
trated, with significant funding flowing into HIV/AIDS, malaria
and tuberculosis product development. Progress is lopsided, with
marked strides in the area of malaria research, yet few end
products in others. This suggests the infusion of more money itself
is insufficient, while better targeting of funds may be warranted.
Moreover, a balanced comprehensive approach to address the
neglected disease problem will involve not only drug development
but also attention paid to public health infrastructure and
capacity-building to improve access.
Supporting Information
Appendix S1 *Trouiller et al. did not include year of approval
for each drug, nor the regulatory agency that made the initial
approval. Using multiple sources, including IMS R&D Focus and
PharmaProjects, we identified both year of approval and the
regulatory agency that made the initial approval. **Trouiller et al.
included fivedrugs on their 1975–1999 approvals list that were not
approved during that period. First, they included pyrazinamide as
a separate NCE. Our research found that this drug was first
approved in 1954. However, we did find that pyrazinamide was
approved as part of a combination product in 1998 (isoniazid +
rifampicin + pyrazinamide + ethambutol). Second, Trouiller et al.
included the atovaquone + proguanil combination as a 1975–1999
approval. However, this combination product was approved in
2000. Therefore, in our list we included it as a 2000–2008
approval. Third, Trouiller et al. included benznidazole as a drug
approved between 1975 and 1999. Our research found that
benznidazole was first approved in 1972. Therefore, we did not
include it on our list of 1975–1999 approvals. Fourth, Trouiller et
al. included nifurtimox as a drug approved between 1975 and
1999. Our research found that nifurtimox was first launched in
1967 as a drug targeting Chagas’ disease. Therefore, we did not
include it on our list of 1975–1999 approvals. Fifth, Trouiller et al.
included pentamidine in the 1975–1999 approvals list. Our
research found that pentamidine was first approved in France in
1956 as a kinetoplastid.
Found at: doi:10.1371/journal.pone.0010610.s001 (0.14 MB
DOC)
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